|
|
Volumn 298, Issue 5593, 2002, Pages
|
|
Cancer drugs: Smart weapons prove tough to design
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PATIENT TREATMENT;
TUMORS;
WEAPONS;
DRUG PRODUCTS;
ANTILEUKEMIC AGENT;
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
BEVACIZUMAB;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEFITINIB;
IMATINIB;
MONOCLONAL ANTIBODY;
PANITUMUMAB;
STEM CELL FACTOR;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
CANCER;
DRUG DEVELOPMENT;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CHRONIC MYELOID LEUKEMIA;
CLINICAL RESEARCH;
CLINICAL TRIAL;
COLORECTAL CANCER;
DRUG APPROVAL;
DRUG DESIGN;
DRUG INDUSTRY;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
HEAD AND NECK CANCER;
HUMAN;
LEUKEMIA;
LEUKEMIA CELL;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
ONCOLOGY;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PHILADELPHIA 1 CHROMOSOME;
PRIORITY JOURNAL;
SHORT SURVEY;
ADVISORY COMMITTEES;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS;
DRUG APPROVAL;
DRUG INDUSTRY;
EPIDERMAL GROWTH FACTOR;
HUMANS;
LUNG NEOPLASMS;
NEOPLASMS;
PATIENT SELECTION;
PIPERAZINES;
PYRIMIDINES;
QUINAZOLINES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 18644364558
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.298.5593.522 Document Type: Short Survey |
|
Times cited : (44)
|
|
References (0)
|